ePharmaSolutions, a provider of technology-based clinical services based in Conshohocken, Penn., has launched PatientLive, an innovative new patient recruitment application for the new Windows 8 platform.
ePharmaSolutions has developed a suite of applications that will help change the way patients are recruited and triaged into clinical studies. The solution includes a consumer and sponsor component that will provide pharmaceutical companies and CROs with a better return on their recruitment investment while providing patients with more information about clinical trials and improved chances to enroll into studies for which they may qualify.
"This is really a game changing application for the pharmaceutical companies and the patients who are interested in participating in research studies," said Lance Converse, founder and CEO, ePharmaSolutions. "We are providing sponsors with ways to optimize their recruitment spend while offering patients personalized, geo-targeted information about new medical therapies and clinical trial opportunities using unique matching algorithms."
Chad Brooks, healthcare partner architect evangelist, Windows 8, Microsoft, said, "ePharmaSolutions has been working closely with Microsoft on the development of several clinical trial applications using SharePoint 2010, Azure and Windows 8. When they came to us with this new idea for improving the patient recruitment process we got involved immediately to offer it as part of the new Windows 8 platform."
The PatientLive app will be an integrated component of an initiative spearheaded by ePharmaSolutions that brings together more than a dozen major pharmaceutical companies and CROs to "share" potential study participants who disqualify for each other's studies—aptly named "Patient Sharing."
The Patient Sharing initiative will leverage the recruitment spend from each of the participating sponsors by immediately presenting people who are deemed ineligible for one study with other pertinent study opportunities based on previous screening responses. Seeing as approximately 90% of people will not qualify for the first study they express interest in, the benefit for pharmaceutical companies to participate in the consortium is clear.
